30 May 2025
  • Blog
  • About
  • Contact
   
  • Current Topics
  • Social Media
  • Innovation
  • Medical Education
  • Residency
  • Research
Headline News
  • Doctors Day 2020 – Anything But Happy 31 Mar 2020
  • Social Media and Professionalism – Protecting Your Patients, Your Profession, and You 30 Oct 2018
  • Reducing the Disclosure Effect in the Vitreoretinal Fellowship Match 24 Oct 2018
  • The Retina Society – 2018 Meeting Highlights 15 Sep 2018
  • Vitreoretinal Fellowship Match Survey – JAMA Ophthalmology 07 May 2018
  • home
  • blog
Sudan Stops River Blindness With Mectizan

Sudan Stops River Blindness With Mectizan

19 May 2012 eyesteve 0 4759

So often as physicians and patients we become frustrated at seemingly ridiculous prices for medications that likely are produced for a fraction of the cost. We view pharmaceutical companies as tyrannical price-gougers that profit from patients, and from patents, at the expense of us all.

While we do not necessarily disagree with this view, recent news from the Panafrican News Agency (PANA) involving pharma tycoon Merck & Co., Inc., should cause all of us to, albeit for a brief moment, put aside our prejudices toward big-pharma, and applaud the efforts made to stop transmission of river blindness throughout the world. PANA announced today that the isolated desert area of Abu Hamad has stopped transmission of river blindness (onchocerciasis). Abu Hamad is notably among the first areas in Africa to demonstrate that intensified mass treatment of the drug Mectizan, donated by Merck, can interrupt transmission of this debilitating disease.

River blindness is caused by the parasitic filarial worm onchocerca volvulus and is transmitted to humans through the bites of black flies near fast-flowing rivers. Worldwide, river blindness is estimated to be the second leading cause of infection-induced blindness, wherein the parasitic worm dies in the eye and leads to chronic inflammation, scarring, and subsequent blindness. River blindness affects 18 million people worldwide, with 800,000 visually impaired, and 270,000 blind.

Starting in 1987, Merck & Co., Inc. committed to donating the Mectizan (Ivermectin) for as long as necessary for the control of river blindness. Though the mechanism of action of Mectizan is unknown, a single, annual dose of Mectizan of 150 to 200 µg/kg has been found to effectively reduce the microfilarial density in the skin to near zero after one month and to successfully maintain a low microfilarial level for up to 12 months, in addition to relieving itching and clearing the parasitic infection from the eye, thus preventing blindness. According to Merck, since the program’s inception in 1987, over 1 billion people have been treated with Mectizan worldwide.

With this exciting news from Sudan, we applaud Merck, as well as the many other pharmaceutical companies and philanthropists who donate countless dollars to vaccinations, medications, infrastructural improvements, and other initiatives both locally and throughout the world. Tonight, when you take your dose of zocor or losartan, and cringe at $$big pharma$$, remember the thousands of individuals in Sudan and worldwide who will never lose their vision thanks to Mectizan stopping transmission of river blindness.

Related

SHARE THIS ARTICLE :
Tweet

We would love to hear what you think! Post your questions or comments below!Cancel reply

ABOUT THE AUTHOR

eyesteve
  • ABOUT ME
  • OTHER ARTICLES
Steve Christiansen, MD, is a vitreoretinal surgeon practicing in Colorado Springs, Colorado. He previously completed ophthalmology residency at the University of Iowa Department of Ophthalmology & Visual Sciences in Iowa City, Iowa and fellowship at the Cincinnati Eye Institute in Cincinnati, Ohio.

Doctors Day 2020 – Anything But Happy

31 Mar 2020 eyesteve 1

Social Media and Professionalism – Protecting Your Patients, Your Profession, and You

30 Oct 2018 eyesteve 0

Reducing the Disclosure Effect in the Vitreoretinal Fellowship Match

24 Oct 2018 eyesteve 0

The Retina Society – 2018 Meeting Highlights

15 Sep 2018 eyesteve 2
PREVIOUS

Researchers Use Skin Cells to Study Retinal Diseases

NEXT

Oculeve - An Exciting Solution to Dry Eye Disease

RELATED POST

Vitreoretinal Fellowship Match Survey – JAMA Ophthalmology

07 May 2018 eyesteve 0

The Return of Private Equity to Ophthalmology

15 Nov 2017 eyesteve 0

Applying to fellowship – application, interview, and travel costs

29 Jan 2017 eyesteve 1

Low vision device using Intel RealSense 3D camera technology

26 Nov 2016 eyesteve 1

FIND EYESTEVE ON SOCIAL MEDIA

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

Subscribe to EyeSteve

Latest Posts

Doctors Day 2020 – Anything But Happy

31 Mar 2020 eyesteve 11323

Social Media and Professionalism – Protecting Your Patients, Your Profession, and You

30 Oct 2018 eyesteve 8721

Reducing the Disclosure Effect in the Vitreoretinal Fellowship Match

24 Oct 2018 eyesteve 8252

Latest Tweets From EyeSteve MD

Follow @eyesteve

EyeSteve.com Logo

EyeSteve.com was created to educate, inform, and inspire all things eye by discussing various aspects of medical education, informing patients about eye diseases and innovative new treatments, and inspiring us all toward vision health and appreciation of the wonderful gift of sight.

Recent Posts

  • Doctors Day 2020 – Anything But Happy
  • Social Media and Professionalism – Protecting Your Patients, Your Profession, and You
  • Reducing the Disclosure Effect in the Vitreoretinal Fellowship Match
  • The Retina Society – 2018 Meeting Highlights
  • Vitreoretinal Fellowship Match Survey – JAMA Ophthalmology

Get EyeSteve In Your Email

Subscribe to eyesteve.com and receive notifications of new posts instantly by email.

Follow @eyesteve
View Steven M. Christiansen's profile on LinkedIn
Copyright 2014 | eyesteve.com | All Rights Reserved | Powered by WordPress